Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Summary

This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab, interferon β-1a 44 μg, or glatiramer acetate.

Timeline

Start

2010-03

Primary completion

2012-04

Completion

2012-04

Drugs

Indications